Patents by Inventor Piyusha Pradeep Pagare

Piyusha Pradeep Pagare has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BENZALDEHYDE COMPOUNDS WITH DIRECT POLYMER DESTABILIZING EFFECTS TO TREAT SICKLE CELL DISEASE
    Publication number: 20240109843
    Abstract: Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are chemically modified to increase bioavailability and activity, e.g., so that the compounds prevent adhesion and sickling of red blood cells (RBCs).
    Type: Application
    Filed: November 3, 2023
    Publication date: April 4, 2024
    Inventors: Martin SAFO, Yan ZHANG, Piyusha Pradeep PAGARE, Guoyan XU, Mohini GHATGE, Jurgen VENITZ, Osheiza ABDULMALIK, Andrew FLEISCHMAN, David LIGHT, Moustafa EL-ARABY, Abdelsattar OMAR
  • AROMATIC ALDEHYDES WITH SUSTAINED AND ENHANCED IN VITRO AND IN VIVO PHARMACOLOGIC ACTIVITY TO TREAT SICKLE CELL DISEASE
    Publication number: 20220340531
    Abstract: Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are based on vanillin which is chemically modified to increase bioavailability and activity, e.g. so that the compounds bind to the F helix of hemoglobin (Hb) and prevent adhesion of red blood cells (RBCs).
    Type: Application
    Filed: June 22, 2022
    Publication date: October 27, 2022
    Inventors: Martin K. SAFO, Yan ZHANG, Piyusha Pradeep PAGARE, Guoyan XU, Mohini GHATGE, Jurgen VENITZ, Osheiza ABDULMALIK
  • Aromatic aldehydes with sustained and enhanced in vitro and in vivo pharmacologic activity to treat sickle cell disease
    Patent number: 11401241
    Abstract: Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are based on vanillin which is chemically modified to increase bioavailability and activity, e.g. so that the compounds bind to the F helix of hemoglobin (Hb) and prevent adhesion of red blood cells (RBCs).
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: August 2, 2022
    Assignees: VIRGINIA COMMONWEALTH UNIVERSITY, THE CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: Martin K. Safo, Yan Zhang, Piyusha Pradeep Pagare, Guoyan Xu, Mohini Ghatge, Jurgen Venitz, Osheiza Abdulmalik